AKTSAktis Oncology, Inc.同业对比
Aktis Oncology, Inc. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AKTS本股 | $755M#8 | — | 1.6x#2 | — | — | — | — | 0.0%#3 | — | — | 18430.2%#1 | — |
| OBX | $890M#1 | — | — | — | — | -21.1%#5 | — | — | — | — | — | — |
| JBIO | $866M#2 | — | 2.0x#5 | — | — | -83.0%#11 | — | -29.0%#6 | — | — | — | — |
| VSTM | $865M#3 | — | 17.3x#11 | 28.0x#4 | 209.1%#1 | -60.3%#10 | -550.3%#4 | -419.1%#12 | — | — | 1.2%#5 | — |
| ANRO | $864M#4 | — | 3.9x#9 | — | — | -2.9%#3 | — | -28.8%#5 | — | — | — | — |
| CYRX | $846M#5 | — | 1.7x#3 | 4.8x#3 | 12.4%#4 | 168.2%#1 | -20.9%#3 | 16.0%#2 | -16.5%#2 | 4#1 | — | — |
| CRVS | $816M#6 | — | 3.6x#8 | — | — | 75.4%#2 | — | -6.8%#4 | — | — | 20.6%#4 | — |
| COLL | $768M#7 | 18.6x#1 | 2.5x#6 | 1.0x#1 | 23.6%#2 | -8.7%#4 | 23.0%#1 | 20.2%#1 | 62.0%#1 | 4#1 | — | — |
| ARDX | $746M#9 | — | 5.0x#10 | 1.8x#2 | 22.1%#3 | -59.0%#9 | -10.1%#2 | -41.6%#9 | -52.3%#3 | — | -50.6%#8 | — |
| AVBP | $675M#10 | — | 1.8x#4 | — | — | -106.6%#12 | — | -45.3%#10 | — | — | -26.8%#7 | — |
| APMD | $659M#11 | — | — | — | — | — | — | — | — | — | — | — |
| DSGN | $651M#12 | — | 3.2x#7 | — | — | -40.7%#8 | — | -34.6%#7 | — | — | 59.9%#3 | — |
| OLMA | $598M#13 | — | 1.4x#1 | — | — | -25.5%#6 | — | -37.7%#8 | — | — | -23.9%#6 | — |
| NVCT | $596M#14 | — | 65.6x#12 | — | — | -39.2%#7 | — | -291.1%#11 | — | — | 172.2%#2 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-03。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议